KerraCel® Ag is a carboxymethyl cellulose (CMC) gelling fiber dressing with Ag Oxysalts™ (Ag3+) designed to help create the optimal healing enviroment.
• Quickly absorbs and locks away exudate and its harmful components
• Micro-contours to the wound bed to eliminate dead space where bacteria can live
• Designed to reduce the risk of periwound maceration
• Strong enough to be removed in one piece
• Kills bacteria within a biofilm and prevents biofilm re-formation
• Quickly kills at least 99.999% of a broad spectrum of bacteria
KerraCel® Ag is indicated for the management of chronic and acute wounds.
KerraCel® Ag vertically wicks and locks excess exudate away from wound bed and periwound skin.
Under the supervision of a health care professional, KerraCel® Ag can be used on the following wounds including: leg ulcers, pressure ulcers, diabetic foot ulcers, surgical wounds, TENS, Stevens-Johnson Syndrome and burns.
KerraCel® Ag is not indicated for surgical implantation, to control heavy bleeding or on individuals who are sensitive to or will have an a allergic reaction to the dressing or its components.
|Absorptive dressing format|
|Alginate dressing format||●|
|Antimicrobial effects up to 48 hours|
|Antimicrobial effects up to 3 days|
|Antimicrobial effects up to 7 days|
|Collagen dressing format|
|Composite dressing format|
|Contact layer dressing format|
|Foam dressing format|
|Gauze or non-woven dressing format|
|Gelling fiber dressing format|
|Hydrogel (amorphous) dressing format|
|Hydrogel (impregnated) dressing format|
|Hydrogel (sheet) dressing format|
|Impermeable to outside contaminants|
|Impregnated dressing format|
|Moisture vapor permeable||●|
|Secondary dressing required||●|
|Super absorbent polymers|
|Sustained release formula|
|Transparent film dressing format|
|Wound filler dressing format|
Moderate/Highly Exudating Wounds
Non/Minimally Exudating Wounds
Acelity leverages the strengths of Kinetic Concepts and Systagenix Wound Management to provide a trusted and complementary portfolio of advanced wound therapeutics for customers and patients in more than 90 countries worldwide.